Nektar Therapeutics will present new 6-month off-treatment data from its Phase 2b REZOLVE-AA study on rezpegaldesleukin for severe alopecia areata at the EADV Congress 2026. The data evaluates the durability of treatment response, highlighting the drug's potential to provide lasting benefits. Additional presentations will cover rezpegaldesleukin's effects in atopic dermatitis and new biomarker findings. An investor call is scheduled for October 1, 2026, to discuss these results in detail.
Nektar's rezpegaldesleukin presentations at EADV Congress 2026 provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Sep 28, 2026 18:42 WIB: out of 100 priced US health stocks, 22 rose and 59 fell. Notable moves include NUWE at USD 0.80 (+3.12%), MRNA at USD 193.30 (-2.81%), and DNA at USD 10.38 (-2.63%).
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
AAR Corp. is set to report strong Q1 earnings with analysts expecting EPS of around $1.29 and revenue near $882 million, up significantly from last year. The company benefits from robust organic growth in aviation parts distribution, supporting healt...
Royal Caribbean Cruises Ltd. is expanding into the all-inclusive resort sector by acquiring a 50% stake in Sandals and Beaches Resorts for $3 billion. This strategic move aims to broaden Royal Caribbean's presence in the $2 trillion global vacation m...
CarMax is set to report its Q3 2026 earnings with analysts predicting an EPS of about $0.73 and revenue near $7.09 billion, indicating growth from last year despite a weak auto market. The company has recently cut 145 corporate jobs as part of ongoin...
Micron Technology is poised for significant growth driven by strong AI demand for its memory products like DRAM, NAND, and HBM4. Analysts have set a price target of $1,520, suggesting a 40% upside from its current price of $1,082. Earnings are expect...
